CLINICAL-IMMUNOLOGICAL ASSESSMENT FAILURE ON INITIAL COMBINATION USE OF ZIDOVUDINE-LAMIVUDINE-NEVIRAPINE IN CHILDREN WITH HIV/AIDS AT SANGLAH HOSPITAL BALI
<p><strong>Background: </strong>Assessing clinical progression and CD4<sup>+</sup> level were important in determining the efficacy of antiretroviral (ARV) and switching to other regimens, especially when viral-load data were not available. <sup> </sup>Thi...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
DiscoverSys
2014-05-01
|
Series: | Bali Medical Journal |
Subjects: | |
Online Access: | https://balimedicaljournal.org/index.php/bmj/article/view/77 |
id |
doaj-a2623324f794463390b6dcc9a8b823eb |
---|---|
record_format |
Article |
spelling |
doaj-a2623324f794463390b6dcc9a8b823eb2020-11-25T03:54:33ZengDiscoverSysBali Medical Journal2089-11802302-29142014-05-013210.15562/bmj.v3i2.7776CLINICAL-IMMUNOLOGICAL ASSESSMENT FAILURE ON INITIAL COMBINATION USE OF ZIDOVUDINE-LAMIVUDINE-NEVIRAPINE IN CHILDREN WITH HIV/AIDS AT SANGLAH HOSPITAL BALIR. Niruri0A. A. S. Maharani1K. D. Kumara2and I. M. Rahajeng3Department of Pharmacy, Faculty of Mathematics and Sciences Udayana University, Bali-IndonesiaDepartment of Pharmacy, Faculty of Mathematics and Sciences Udayana University, Bali-IndonesiaDepartment of Pediatry, Sanglah General Hospital, Bali-IndonesiaFaculty of Medicine, Udayana University, Bali-Indonesia<p><strong>Background: </strong>Assessing clinical progression and CD4<sup>+</sup> level were important in determining the efficacy of antiretroviral (ARV) and switching to other regimens, especially when viral-load data were not available. <sup> </sup>This research aims to assess combination of zidovudine-lamivudine-nevirapine (Co-ZLN) failure using WHO 2010 criteria on clinical failure (CF) and immunological failure (IF), single or together, to determine correlation between CF and IF; and to evaluate two failure categories (CF alone and combination of CF-IF) in making decision to switch to second-line of ARV. <strong>Methods:</strong> Children at Sanglah General Hospital, who gain initial treatment of Co-ZLN in period of March 2006–March 2013 were selected. Cross-sectional study was applied. The ARV response was assessed twice. First period (P1) and second period (P2) of evaluation were conducted after patients received the Co-ZLN at least 6 and 12 months. <strong>Results:</strong> Forty five patients were included in this study. After at least 6 and 12 months of therapy, more patients showed IF (10 and 9 children in P1 and P2) than those in CF (4 and 2 patients in P1 and P2). Only one child met to CF-IF category in P2. The low clinical condition (HIV stage 4) did not always associate with deteriorating immunologic marker in the treatment-failure (TF). The patients who fit on CF and CF-IF based decision to switch regimen criteria were different. In resource-limited hospital, CF-IF based decision could give a better picture of patients’ condition and be used as an indicator to assess TF compared to single CF criteria.</p>https://balimedicaljournal.org/index.php/bmj/article/view/77first-line arv, failure, children |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
R. Niruri A. A. S. Maharani K. D. Kumara and I. M. Rahajeng |
spellingShingle |
R. Niruri A. A. S. Maharani K. D. Kumara and I. M. Rahajeng CLINICAL-IMMUNOLOGICAL ASSESSMENT FAILURE ON INITIAL COMBINATION USE OF ZIDOVUDINE-LAMIVUDINE-NEVIRAPINE IN CHILDREN WITH HIV/AIDS AT SANGLAH HOSPITAL BALI Bali Medical Journal first-line arv, failure, children |
author_facet |
R. Niruri A. A. S. Maharani K. D. Kumara and I. M. Rahajeng |
author_sort |
R. Niruri |
title |
CLINICAL-IMMUNOLOGICAL ASSESSMENT FAILURE ON INITIAL COMBINATION USE OF ZIDOVUDINE-LAMIVUDINE-NEVIRAPINE IN CHILDREN WITH HIV/AIDS AT SANGLAH HOSPITAL BALI |
title_short |
CLINICAL-IMMUNOLOGICAL ASSESSMENT FAILURE ON INITIAL COMBINATION USE OF ZIDOVUDINE-LAMIVUDINE-NEVIRAPINE IN CHILDREN WITH HIV/AIDS AT SANGLAH HOSPITAL BALI |
title_full |
CLINICAL-IMMUNOLOGICAL ASSESSMENT FAILURE ON INITIAL COMBINATION USE OF ZIDOVUDINE-LAMIVUDINE-NEVIRAPINE IN CHILDREN WITH HIV/AIDS AT SANGLAH HOSPITAL BALI |
title_fullStr |
CLINICAL-IMMUNOLOGICAL ASSESSMENT FAILURE ON INITIAL COMBINATION USE OF ZIDOVUDINE-LAMIVUDINE-NEVIRAPINE IN CHILDREN WITH HIV/AIDS AT SANGLAH HOSPITAL BALI |
title_full_unstemmed |
CLINICAL-IMMUNOLOGICAL ASSESSMENT FAILURE ON INITIAL COMBINATION USE OF ZIDOVUDINE-LAMIVUDINE-NEVIRAPINE IN CHILDREN WITH HIV/AIDS AT SANGLAH HOSPITAL BALI |
title_sort |
clinical-immunological assessment failure on initial combination use of zidovudine-lamivudine-nevirapine in children with hiv/aids at sanglah hospital bali |
publisher |
DiscoverSys |
series |
Bali Medical Journal |
issn |
2089-1180 2302-2914 |
publishDate |
2014-05-01 |
description |
<p><strong>Background: </strong>Assessing clinical progression and CD4<sup>+</sup> level were important in determining the efficacy of antiretroviral (ARV) and switching to other regimens, especially when viral-load data were not available. <sup> </sup>This research aims to assess combination of zidovudine-lamivudine-nevirapine (Co-ZLN) failure using WHO 2010 criteria on clinical failure (CF) and immunological failure (IF), single or together, to determine correlation between CF and IF; and to evaluate two failure categories (CF alone and combination of CF-IF) in making decision to switch to second-line of ARV. <strong>Methods:</strong> Children at Sanglah General Hospital, who gain initial treatment of Co-ZLN in period of March 2006–March 2013 were selected. Cross-sectional study was applied. The ARV response was assessed twice. First period (P1) and second period (P2) of evaluation were conducted after patients received the Co-ZLN at least 6 and 12 months. <strong>Results:</strong> Forty five patients were included in this study. After at least 6 and 12 months of therapy, more patients showed IF (10 and 9 children in P1 and P2) than those in CF (4 and 2 patients in P1 and P2). Only one child met to CF-IF category in P2. The low clinical condition (HIV stage 4) did not always associate with deteriorating immunologic marker in the treatment-failure (TF). The patients who fit on CF and CF-IF based decision to switch regimen criteria were different. In resource-limited hospital, CF-IF based decision could give a better picture of patients’ condition and be used as an indicator to assess TF compared to single CF criteria.</p> |
topic |
first-line arv, failure, children |
url |
https://balimedicaljournal.org/index.php/bmj/article/view/77 |
work_keys_str_mv |
AT rniruri clinicalimmunologicalassessmentfailureoninitialcombinationuseofzidovudinelamivudinenevirapineinchildrenwithhivaidsatsanglahhospitalbali AT aasmaharani clinicalimmunologicalassessmentfailureoninitialcombinationuseofzidovudinelamivudinenevirapineinchildrenwithhivaidsatsanglahhospitalbali AT kdkumara clinicalimmunologicalassessmentfailureoninitialcombinationuseofzidovudinelamivudinenevirapineinchildrenwithhivaidsatsanglahhospitalbali AT andimrahajeng clinicalimmunologicalassessmentfailureoninitialcombinationuseofzidovudinelamivudinenevirapineinchildrenwithhivaidsatsanglahhospitalbali |
_version_ |
1724473108495073280 |